CANbridge Pharmaceuticals (1228.HK) Earnings Analysis
CANbridge Pharmaceuticals (1228.HK) next reports earnings on 2026-09-02. Trailing P/E 36.45.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 1228.HK next report earnings?
| Next earnings date | 2026-09-02 |
|---|---|
| Consensus EPS estimate | n/a |
| Revenue estimate | n/a |
1228.HK earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-08-31 | 0.1534 HKD | n/a | n/a | n/a |
| 2024-12-31 | -0.24458 HKD | n/a | n/a | n/a |
| 2024-09-30 | -0.25441 HKD | n/a | n/a | n/a |
1228.HK valuation and analyst view
| Trailing P/E | 36.45 |
|---|---|
| Trailing EPS | 0.03106 HKD |
| Price / book | -2.41 |
| Dividend yield | 0.00% |
| Market cap | 0.84B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is CANbridge Pharmaceuticals (1228.HK)'s next earnings date?
CANbridge Pharmaceuticals is next scheduled to report on 2026-09-02.
Did 1228.HK beat earnings last quarter?
Consensus estimate data was not available for 1228.HK's 2025-08-31 report.
What is 1228.HK's current P/E ratio and EPS?
1228.HK trades at a trailing P/E of 36.45 on trailing EPS of 0.03106242436067507 HKD.
What do analysts rate 1228.HK?
1228.HK has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.